Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C21H23NO3·HCl
CAS Number:
Molecular Weight:
373.87
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
solid
solubility
H2O: ≥20 mg/mL
storage temp.
room temp
SMILES string
Cl.CN(C)CC\C=C1\c2ccccc2COc3ccc(CC(O)=O)cc13
InChI
1S/C21H23NO3.ClH/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24;/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24);1H/b18-8-;
InChI key
HVRLZEKDTUEKQH-NOILCQHBSA-N
Gene Information
human ... HRH1(3269)
Biochem/physiol Actions
Olopatadine is a dual acting histamine H1-receptor antagonist and mast cell stabilizer.
Olopatadine is a histamine H1 receptor antagonist and mast cell stabilizer. The low level of occupancy H1 receptors in the brain explains the low sedation effect of olopatidine. It is believed that olopatidine is a substrate for P-glycoprotein, which limits its brain penetration.
Still not finding the right product?
Explore all of our products under Olopatadine hydrochloride
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Aquatic Acute 1
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Eli O Meltzer et al.
Allergy and asthma proceedings, 32(3), 213-220 (2011-04-12)
Allergic rhinitis (AR) is highly prevalent in children. Olopatadine, 0.6% nasal spray (olopatadine) is approved for the relief of seasonal allergic rhinitis (SAR) symptoms in children 6 years of age and older. The objective of this study is to provide
Fuad M Baroody et al.
American journal of rhinology & allergy, 27(1), 48-53 (2013-02-15)
Nasal allergen challenge (NAC) leads to a nasal ocular reflex, which is augmented by allergic inflammation. This study was designed to confirm our previous observation that an intranasal steroid inhibits the nasal ocular reflex and to show that histamine does
Masahiko Shimura et al.
American journal of ophthalmology, 151(4), 697-702 (2011-01-25)
To evaluate the effectiveness of pre-seasonal treatment with topical olopatadine on the reduction of clinical symptoms of seasonal allergic conjunctivitis (SAC). Prospective interventional case series. Eleven patients with SAC received topical olopatadine in one eye at least two weeks before

